These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15620848)

  • 21. Steroids in the Guillain-Barré syndrome: is there a therapeutic window?
    Van Koningsveld R; Van Doorn PA
    Neurologia; 2005 Mar; 20(2):53-7. PubMed ID: 15726470
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group.
    Ann Neurol; 1994 Jun; 35(6):749-52. PubMed ID: 8210234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similarities of serum anti-ganglioside antibodies in first and third episodes of recurrent Guillain-Barre syndrome: case report.
    Togawa J; Nakaoku Y; Hagiwara M; Murakami G; Mitsueda-Ono T; Ueno R; Kusunoki S; Matsui M
    J Neurol; 2015 May; 262(5):1360-2. PubMed ID: 25845761
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.
    Jacobs BC; O'Hanlon GM; Bullens RW; Veitch J; Plomp JJ; Willison HJ
    Brain; 2003 Oct; 126(Pt 10):2220-34. PubMed ID: 12876146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacterial infections in Guillain-Barré and Fisher syndromes.
    Yuki N; Koga M
    Curr Opin Neurol; 2006 Oct; 19(5):451-7. PubMed ID: 16969154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Campylobacter jejuni DNA-binding protein from starved cells in Guillain-Barré syndrome patients.
    Kawamura N; Piao H; Minohara M; Matsushita T; Kusunoki S; Matsumoto H; Ikenaka K; Mizunoe Y; Kira J
    J Neuroimmunol; 2011 Dec; 240-241():74-8. PubMed ID: 21996079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies.
    Souza PV; Pinto WB; Oliveira AS
    Arq Neuropsiquiatr; 2014 Dec; 72(12):966-71. PubMed ID: 25465778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation.
    Kuijf ML; Samsom JN; van Rijs W; Bax M; Huizinga R; Heikema AP; van Doorn PA; van Belkum A; van Kooyk Y; Burgers PC; Luider TM; Endtz HP; Nieuwenhuis EE; Jacobs BC
    J Immunol; 2010 Jul; 185(1):748-55. PubMed ID: 20525894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axonal Guillain-Barré syndrome: concepts and controversies.
    Kuwabara S; Yuki N
    Lancet Neurol; 2013 Dec; 12(12):1180-8. PubMed ID: 24229616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Guillain-Barré syndrome with intravenous methylprednisolone.
    Hughes R; Swan A
    Ann Neurol; 1995 May; 37(5):683-4. PubMed ID: 7755366
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
    Yuki N; Ang CW; Koga M; Jacobs BC; van Doorn PA; Hirata K; van der Meché FG
    Ann Neurol; 2000 Mar; 47(3):314-21. PubMed ID: 10716250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of methylprednisolone in patients with Guillain-Barré syndrome.
    Rossi G; Locatelli F
    Lancet; 2004 Apr; 363(9416):1237; author reply 1237-8. PubMed ID: 15081665
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant interferon-beta therapy and neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2009 Jul; 212(1-2):132-41. PubMed ID: 19443048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of intravenous immunoglobulins in the treatment of neuromuscular disorders.
    Voltz R; Hohlfeld R
    Curr Opin Neurol; 1996 Oct; 9(5):360-6. PubMed ID: 8894412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)].
    Nishida H; Kuroda T; Wakita K
    Nihon Rinsho; 2008 Jun; 66(6):1190-4. PubMed ID: 18540369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of axonal form of Guillain-Barré syndrome associated with anti-GM1b IgG antibody following Penner 4 Campylobacter jejuni infection].
    Nagayama S; Kurohara K; Matsui M; Kuroda Y; Kusunoki S
    Rinsho Shinkeigaku; 1997 Jun; 37(6):506-8. PubMed ID: 9366179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC
    Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Campylobacter jejuni infection in patient with Guillain-Barré syndrome: a case report].
    Kopyta I; Wardak S
    Med Dosw Mikrobiol; 2008; 60(1):59-63. PubMed ID: 18634345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flagella as a potential marker for Campylobacter jejuni strains associated with Guillain-Barré syndrome.
    Tsang RS; Figueroa G; Bryden L; Ng L
    J Clin Microbiol; 2001 Feb; 39(2):762-4. PubMed ID: 11158146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbohydrate mimicry of Campylobacter jejuni lipooligosaccharide is critical for the induction of anti-GM1 antibody and neuropathy.
    Shu XM; Cai FC; Zhang XP
    Muscle Nerve; 2006 Feb; 33(2):225-31. PubMed ID: 16270308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.